Podcasts about pathology and lab medicine

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/accurate-diagnosis-and-management-of-hereditary-alpha-tryptasemia/32716/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-treatment-of-systemic-mastocytosis-with-an-associated-hematologic-neoplasm/32715/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/is-it-nonresponsiveprogressive-ism/32714/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/differential-diagnosis-of-indolent-systemic-mastocytosis/32713/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease. FA-11319389 12/24

Guest: Donald Kohan, MD, PhD Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City. References: Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143 Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023 Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321 Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301 Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670 FA-11319389 12/24

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-evidence-that-drives-current-guidelines-for-patients-with-cllsll-and-mcl-receiving-third-line-therapies/32285/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-concordant-care-for-patients-with-cllsll-relapsing-after-2-prior-lines-of-therapy/32286/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-with-potentially-guideline-changing-implications-in-cllsll-and-mcl/32287/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-monotherapy-in-the-second-line-or-later-setting-in-metastatic-urothelial-cancer/29194/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-frontline-immunotherapy-based-combination-regimens-in-metastatic-urothelial-cancer/29193/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-concordant-care-for-first-line-treatment-of-a-patient-with-metastatic-urothelial-carcinoma/29195/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-first-line-treatment-intensification-with-parp-inhibitor-combinations-in-patients-with-metastatic-castration-resistant-prostate-cancer/29196/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-recommendations-into-the-frontline-care-of-a-patient-with-mcrpc-who-is-naive-to-both-docetaxel-and-novel-hormone-therapy/29197/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-first-line-treatment-with-immunotherapy-and-targeted-therapy-combinations-in-renal-cell-carcinoma/29198/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-second-line-treatment-following-an-immune-checkpoint-inhibitor-in-renal-cell-carcinoma/29199/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-targeted-therapy-combination-strategies-in-genitourinary-malignancies/29200/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-immunotherapy-combination-strategies-in-genitourinary-malignancies/29201/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-optimizing-patient-care-in-genitourinary-malignancies/29202/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Grady, MD While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.

CME credits: 0.75 Valid until: 02-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-role-of-met-tkis-in-nsclc/17986/ The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease. =

CME credits: 0.25 Valid until: 29-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consensus-recommendations-for-use-of-p16ki67-dual-staining-cytology-in-the-management-of-individuals-testing-positive-for-hpv/14675/ More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.=

CME credits: 0.25 Valid until: 07-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-potential-of-trop2-targeted-therapy-breakthroughs-in-nsclc-therapeutic-approaches/16212/ Drs. Benjamin Levy and Alex Spira discuss the emerging role of TROP2 as a therapeutic target in non-small cell lung cancer (NSCLC) on ReachMD. They delve into the mechanisms and clinical implications of TROP2-targeted antibody-drug conjugates (ADCs), highlighting ongoing clinical trials evaluating their safety and efficacy. The conversation covers the potential of these therapies to change treatment paradigms, especially in the context of TROP2 overexpression associated with poor prognosis in lung cancers. They also address the nuances of managing side effects and the importance of understanding TROP2's role in cancer regulation, underscoring the significance of keeping up-to-date with the latest clinical trial data in this rapidly evolving field.=

CME credits: 0.50 Valid until: 07-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-potential-of-her3-targeted-therapy-breakthroughs-in-egfr-mutant-nsclc-therapeutic-approaches/16214/ Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.=

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-acquired-tki-resistance-with-next-generation-ros1-tki-agents/18161/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-treatment-selection-for-ros1-rearranged-nsclc-patient-with-brain-metastases/18162/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/treatment-strategy-of-ros1-rearranged-nsclc-in-tki-naive-patient/18160/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-chemotherapy-and-immunotherapy-in-ros1-rearranged-nsclc/18159/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-ros1-tyrosine-kinase-inhibitors/18158/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/intracranial-activity-of-ros1-tkis/18157/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/later-line-targeted-therapies-for-ros1-fusion-positive-lung-cancers/18156/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/first-line-targeted-therapies-for-ros1-fusion-positive-lung-cancers/18155/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-guidelines-and-real-world-evidence-for-ros1-testing-in-nsclc/18154/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

CME credits: 0.25 Valid until: 28-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-potential-of-her2-targeted-therapy-breakthroughs-in-nsclc-therapeutic-approaches/16213/ Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.=

CME credits: 0.25 Valid until: 11-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-breaking-barriers-advances-in-treating-egfr-exon-20-insertions-in-nsclc/16082/ We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.=

CME credits: 0.25 Valid until: 15-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-her2-unveiling-new-horizons-in-nsclc-treatment/16083/ We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.=

CME credits: 0.25 Valid until: 25-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/met-inhibition-in-metastatic-nsclc-in-the-spotlight/14786/ Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we're learning to everyday clinical practice.=

CME credits: 1.00 Valid until: 25-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/new-treatments-for-residual-excessive-daytime-sleepiness-in-obstructive-sleep-apnea/16027/ This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-future-of-adcs-in-metastatic-tnbc/15812/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-do-patientscaregivers-need-to-know-about-adcs-in-metastatic-tnbc/15811/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/how-are-we-addressing-unanswered-questions-around-adcs-in-metastatic-tnbc/15810/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-factors-impact-use-of-adcs-in-special-patient-populations-with-metastatic-tnbc/15809/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/metastatic-tnbc-utilizing-biology-and-health-disparities-to-inform-shared-decision-making/15808/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-evidence-for-adcs-in-hr-her2-low-metastatic-breast-cancer/15807/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-apply-evidence-supporting-trop2-directed-adcs-to-the-metastatic-tnbc-treatment-paradigm/15806/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/which-tnbc-patients-are-eligible-for-adcs/15805/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/adc-targets-does-positivity-really-matter/15804/ This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 17-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-and-managing-adverse-effects-with-adcs-in-hr-breast-cancer-strategies-to-improve-outcomes/15791/ This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient's quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

CME credits: 1.00 Valid until: 17-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-for-trop2-targeted-adcs-in-hrher2-positive-and-her2-low-mbc/15789/ This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient's quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.